Casticin inhibits epithelial-mesenchymal transition of liver cancer stem cells of the smmc-7721 cell line through downregulating twist

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1625-1631

  He, Meng ^a   Cao, Xiao Cheng ^b   He, Gui Cheng ^a   Sheng, Xi Feng ^b   Ai, Xiao Hong ^a   Wu, You Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Casticin; Epithelial mesenchymal transition; Hepatocellular carcinoma; Twist

Indexed keywords

ANTINEOPLASTIC AGENT; CASTICIN; CD133 ANTIGEN; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL SELECTION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CANCER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE SECTION; WESTERN BLOTTING;

EID: 84896293972     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1899     Document Type: Article

References (34)

1. Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394-399, 2012.
5. Aguayo A and Patt YZ: Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 28: 503-513, 2001.
6. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.
7. Kuvshinoff BW and Ota DM: Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 132: 605-611; discussion 611-612, 2002.
8. Zhou BB, Zhang H, Damelin M, et al: Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823, 2009.
9. Suetsugu A, Nagaki M, Aoki H, et al: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824, 2006.
10. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450, 2007.
11. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007.
12. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758, 2008.
13. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
14. Morel AP, Lièvre M, Thomas C, et al: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
15. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
16. Gavert N and Ben-Ze'ev A: Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14: 199-209, 2008.
17. Lee TK, Poon RT, Yuen AP, et al: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12: 5369-5376, 2006.
18. Li Y, Wicha MS, Schwartz SJ and Sun D: Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22: 799-806, 2011.
19. Li Y, Zhang T, Korkaya H, et al: Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 16: 2580-2590, 2010.
20. Rausch V, Liu L, Kallifatidis G, et al: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013, 2010.
21. Haidara K, Zamir L, Shi QW and Batist G: The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett 242: 180-190, 2006.
22. Zhou Y, Peng Y, Mao QQ, et al: Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Asian Pac J Trop Med 6: 372-378, 2013.
23. Kobayakawa J, Sato-Nishimori F, Moriyasu M and Matsukawa Y: G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil.). Cancer Lett 208: 59-64, 2004.
24. Ko WG, Kang TH, Lee SJ, et al: Polymethoxyflavonoids from Vitex rotundifolia inhibit proliferation by inducing apoptosis in human myeloid leukemia cells. Food Chem Toxicol 38: 861-865, 2000.
25. Lin S, Zhang H, Han T, Wu JZ, Rahman K and Qin LP: In vivo effect of casticin on acute inflammation. Zhong Xi Yi Jie He Xue Bao 5: 573-576, 2007.
26. Yang J, Yang Y, Tian L, Sheng XF, Liu F and Cao JG: Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol 17: 4298-4307, 2011.
27. He L, Yang X, Cao X, Liu F, Quan M and Cao J: Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep 29: 103-108, 2013.
28. El-Haibi CP, Bell GW, Zhang J, et al: Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA 109: 17460-17465, 2012.
29. Barr MP, Gray SG, Hoffmann AC, et al: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193, 2013.
30. Gavert N and Ben-Ze'ev A: Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14: 199-209, 2008.
31. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749, 2005.
32. Song W, Li H, Tao K, et al: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218, 2008.
33. Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
34. Kang Y and Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004.